The purpose of this clinical study is to test how taking zenagamtide tablets with different meal/water variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity. All participants will get zenagamtide.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
320
Zenagamtide will be administered to one of the body parts: thigh, abdomen or upper arm
Zenagamtide tablet will be taken in the morning in fasted state.
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, Germany
AUC, zenagamtide, steady state (ss): area under the zenagamtide plasma concentration-time curve during a dosing interval at steady state
Measured as nanomoles per liter hourly (h\*nmol/L)
Time frame: From 0 (pre-dose) up to Day 196 and Day 224
Cmax, zenagamtide, ss: maximum observed plasma concentration of zenagamtide at steady state
Measured as nanomoles per liter (nmol/L)
Time frame: From Day 196 to Day 197 and from Day 224 to Day 225
tmax, zenagamtide, ss: the time to maximum observed plasma concentration of zenagamtide at steady state
Measured as hours
Time frame: From Day 196 to Day 197 and from Day 224 to Day 225
t1/2, ss; the terminal half-life of zenagamtide after the last dose
Measured as hours
Time frame: From pre-dose on Day 224 until completion of Day 252
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.